AZ, Sanofi prep filings for one-shot RSV antibody after tria...

AstraZeneca and Sanofi now have the data they need in hand to press ahead with regulatory filings next year for nirsevimab, an antibody designed to prevent respiratory syncytial virus (RSV)

NICE backs Sobi's Kineret for rare inflammatory disease

The UK's cost-effectiveness agency NICE has recommended that Sobi's Kineret can be used to treat NHS patients with Still's disease, a rare form of arthritis affecting children and adults.

Sobi gets EU nod for Doptelet in rare blood disorder ITP

Sweden’s Sobi has secured EU approval for Doptelet in primary chronic immune thrombocytopenia (ITP), an indication that the company expects to accelerate sales of the drug.

Sobi stays on its acquisitive streak with $915m Dova deal

Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova

AZ buys cut price priority review voucher, but for what?

Sobi cuts staff and buys Novimmune drug in refocus

Sobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst taking full control of a drug it licenses from Novimmune.